{"id":531990,"date":"2021-02-26T20:28:01","date_gmt":"2021-02-26T20:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531990"},"modified":"2021-02-26T20:28:01","modified_gmt":"2021-02-26T20:28:01","slug":"nonalcoholic-steatohepatitis-market-market-insights-and-market-trend-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonalcoholic-steatohepatitis-market-market-insights-and-market-trend-by-delveinsight_531990.html","title":{"rendered":"Nonalcoholic Steatohepatitis Market: Market Insights and Market Trend by DelveInsight"},"content":{"rendered":"
\"Nonalcoholic<\/a><\/div>\n

DelveInsight has launched a new report on Nonalcoholic Steatohepatitis Market<\/strong><\/a><\/span><\/p>\n

 <\/p>\n

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.<\/p>\n

 <\/p>\n

The key players elaborated in the Nonalcoholic Steatohepatitis Market report includes <\/strong>Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics) ,Galmed Pharmaceuticals Ltd., Bristol-Myers Squibb (BMS), Immuron Galectin Therapeutics, Cirius Therapeutics, NGM Biopharmaceuticals, TaiwanJ Pharmaceuticals, And many others<\/p>\n

 <\/p>\n

Download Free Report Sample- https:\/\/www.delveinsight.com\/sample-request\/nonalcoholic-steatohepatitis-nash-market <\/a><\/span><\/strong><\/p>\n

 <\/p>\n

The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4). According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death.<\/p>\n

 <\/p>\n

Nonalcoholic Steatohepatitis Market Key Companies<\/strong><\/p>\n